TRIPLE NEGATIVE BREAST CANCER SCREEN AND METHODS OF USING SAME IN PATIENT TREATMENT SELECTION AND RISK MANAGEMENT

摘要

Disclosed are methods and kits useful for selecting a treatment for a triple negative breast cancer (TNBC) patient. The method involves assessing expression levels of a panel of TNBC biomarker genes that are specific for a gene set correlated to chemotherapeutic agent sensitivity to a mitosis-inhibiting chemotherapeutic agent (such as anthracycline-taxane (AT)-chemotherapy) in a TNBC patient, deriving a score from the gene expression values, and using the score to identify the level of sensitivity of the patient to the mitosis-inhibiting chemotherapeutic treatment. The most appropriate treatment for the TNBC patient may then be selected. Kits may include a set of TNBC biomarker gene molecular probes, and an instructional insert providing steps on calculating a TNBC patient response score, and classifying the TNBC patient as having a high sensitivity or low sensitivity for a mitosis-inhibiting chemotherapeutic regimen (such as AT-chemotherapy), based on the patient's TNBC response score.